Ziopharm Oncology (ZIOP) Prices 27.826M Share Common Offering at $3.25/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Ziopharm Oncology (ZIOP) Announces Proposed Common Share Offering
February 7, 2020 5:56 AM ESTZiopharm Oncology, Inc. (NASDAQ: ZIOP) today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Ziopharm. Ziopharm also intends to grant the... More
Pre-Open Stock Movers 2/5: (ABUS) (COTY) (QGEN) Higher (PLT) (KN) (SNAP) Lower (more...)
February 5, 2020 9:15 AM ESTPre-Open Stock Movers
Plantronics (NYSE: PLT) 30% LOWER; reported Q3 EPS of $0.30, $0.16 better than the analyst estimate of $0.14. Revenue for the quarter came in at $392 million versus the consensus estimate of $400.51 million. Plantronics sees Q4 2020 EPS of ($0.36)-$0.19, versus the consensus of $0.51. Plantronics sees Q4 2020 revenue of $354-394 million, versus the consensus of $441 million.
Ziopharm Oncology (ZIOP) Prices 27.83M Share Common Offering at $3.25/Sh
February 5, 2020 9:03 AM ESTZiopharm Oncology, Inc. (NASDAQ: ZIOP) today announced the pricing of an underwritten public offering of 27,826,086 shares of its common stock at a public offering price of $3.25 per share. Ziopharm has granted the underwriters a 30-day option to purchase up to an additional 4,173,912... More
